The Food and Drug Administration is requiring a warning about a rare eye condition on the labeling of every approved GLP-1 drug — the class used for type 2 diabetes and weight loss that includes Ozempic, Wegovy, Mounjaro and Zepbound.
In a drug safety communication dated Nov. 9, 2026, the agency said makers must add to the Warnings and Precautions section of each label what it calls "a potential increased risk" of NAION — a condition that follows a drop in blood flow to the optic nerve and can cause sudden, painless and sometimes permanent vision loss in one eye.
The numbers
The FDA's own pooled analysis of 126 randomized, controlled trials, covering 134,253 patients, counted 6.4 NAION cases per 100,000 person-years among patients taking a GLP-1 drug, against 3.8 among those given a placebo or a different glucose-lowering medicine.
Citing published literature, the agency puts the condition's background rate at 2.3 to 10.2 cases per 100,000 people a year in adults older than 50. Which is to say the observed rate among GLP-1 users sits comfortably inside the background range — a detail worth keeping in mind before the headlines announce that your weight-loss injection is blinding you.
The comparison
The agency also compared NAION rates in its Sentinel health-data system among adults with type 2 diabetes who started a GLP-1 or another diabetes drug between 2019 and 2024.
Against DPP-4 inhibitors, an older class of diabetes pills, the FDA reported a higher risk. Against SGLT-2 inhibitors, it found no significant difference.
So the signal is not uniform across comparators. It depends on what you are comparing to — a nuance that tends to vanish in the retelling.
The mechanism problem
The FDA said animal data showed no mechanism by which a GLP-1 drug could raise the risk, and that NAION's cause is not completely understood.
Its known risk factors — among them diabetes and sleep apnea — are common in patients who take these drugs.
That is the awkward part. The population taking GLP-1 drugs is, by definition, a population already at elevated baseline risk for the condition the label now warns about. Separating drug effect from underlying risk is not straightforward, and the agency does not claim to have done so.
What patients are told to watch for
Sudden, painless vision loss in one eye, which they may notice on waking, as well as blurred or missing areas of vision.
"Patients should contact their health care professional right away if they have any of these symptoms," the FDA wrote.
Where this came from
The agency said it opened the review after a July 2024 paper in JAMA Ophthalmology by Hathaway and colleagues on NAION in patients prescribed semaglutide. Cases have been reported for every GLP-1 product on the market.
So: a rare condition, a modest signal in pooled trial data, a comparator-dependent result in real-world data, no established mechanism in animals, and a patient population whose baseline risk is already elevated. The warning goes on every label anyway.
That is not unreasonable. A label warning is a low-cost intervention, and sudden vision loss is not a trivial thing to miss. But it is also not a finding that the drugs cause NAION. The FDA says "potential increased risk." The word "potential" is doing a lot of work in that sentence, and it deserves to be read as written.
